FDA Gives Nod To IntelGenx’s Migraine Solution As Revenues Plunge 32%; Q1 Results Report – Intelgenx Technologies (OTC:IGXT)
IntelGenx Technologies Corp. IGXT reported on Thursday a 32% decrease in total revenues for the first quarter of 2023, amounting to $162,000 as compared to $237,000 in the same period last year. The company’s net comprehensive loss was $2.9 million, slightly lower than the $3.0 million loss in the first quarter of 2022. Adjusted EBITDA loss increased […]